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Abstract 17 
Local production of estrogen rapidly follows brain tissue injury, but the role this hormone plays in 18 
regulating the response to neural damage or in the modulation of mediators regulating inflammation is 19 
in many ways unclear. Using the murine BV2 microglia model as well as primary microglia from wild-20 
type and annexin A1 (AnxA1) null mice, we have identified two related mechanisms whereby estradiol 21 
can modulate microglial behaviour in a receptor specific fashion. Firstly, estradiol, via estrogen 22 
receptor β (ERβ), enhanced the phagocytic clearance of apoptotic cells, acting through increased 23 
production and release of the protein AnxA1. Secondly, stimulation of either ERβ or the G protein 24 
coupled estrogen receptor GPER promoted the adoption of an anti-inflammatory/pro-resolving 25 
phenotype, an action similarly mediated through AnxA1. Together, these data suggest the hypothesis 26 
that locally produced estrogen acts through AnxA1 to exert powerful pro-resolving actions, controlling 27 
and limiting brain inflammation and ultimately protecting this highly vulnerable organ. Given the high 28 
degree of receptor selectivity in evoking these responses, we suggest that the use of selective estrogen 29 
receptor ligands may hold therapeutic promise in the treatment of neuroinflammation, avoiding 30 
unwanted generalised effects.  31 
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Introduction 32 
The neuroprotective potential of the steroid hormone estrogen has been the focus of numerous 33 
investigations, with epidemiological and animal model studies suggesting it may protect in conditions 34 
as diverse as stroke, Alzheimer’s disease, Parkinson’s disease and traumatic brain injury (1). Despite 35 
this, detailed understanding of the mechanisms underlying its actions in the brain remains elusive. 36 
Many studies have focused upon the direct effects of estrogen upon damaged/dying neurones, but it is 37 
only relatively recently that the relationship between estrogen and the innate defence mechanisms of 38 
the brain, principally astrocytes and microglia, has begun to be addressed (2,3). 39 
 40 
Local production of estrogen by astrocytes is one of the first responses of both male and female brain 41 
tissue to injury (4), with this production affording significant protection in vivo (5). Dysregulated 42 
inflammation can be extremely deleterious for the brain (6), hence studies have focused on suppressive 43 
actions of estradiol, revealing its ability to limit microglial iNOS activity (7), and production of reactive 44 
oxygen species (8), prostaglandins (9) and inflammatory cytokines (10).  45 
 46 
However, it is becoming increasingly clear that in the absence of aggravating factors inflammation is 47 
naturally self-limiting, with many classical mediators activating resolving pathways (11). This may 48 
have significant consequences for future therapeutic development, as generalized suppression of 49 
microglial activity significantly worsens neuronal loss in several animal models (12,13), indicating the 50 
complexity of the neuroinflammatory response. We hypothesized that the actions of estrogen upon 51 
microglia are more complex than simply reducing pro-inflammatory mediator production, and that it 52 
may actively promote pro-resolving/anti-inflammatory microglial behaviour.  53 
 54 
Whilst the mechanisms of neuroinflammatory resolution are relatively underexplored, significant 55 
efforts have been made to understand the drivers of this process in peripheral inflammation (14). Many 56 
mediators have been shown to aid in inflammatory resolution and repair, but a key driver of this process 57 
is the glucocorticoid-inducible protein annexin A1 (ANXA1), which we and others have shown to exert 58 
numerous pro-resolving/anti-inflammatory effects including promotion of neutrophil endothelial 59 
detachment (15) and apoptosis (16), monocyte recruitment (17,18) and macrophage phagocytosis (19). 60 
CNS expression of ANXA1 is primarily localised to endothelial cells (20) and the microglia, where we 61 
have previously shown it to be a critical player in microglial efferocytosis (21). Moreover, several 62 
studies have shown that ANXA1 expression in immune and other cells can be enhanced by estradiol 63 
(22–24), suggesting that the role of this protein in anti-inflammatory/pro-resolving actions of estradiol 64 
merits investigation.  65 
 66 
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Microglial phagocytosis, the removal of potentially damaging threats such as invading pathogens or 67 
apoptotic cells, is central to their ability to respond to neuroinflammatory challenge. We therefore 68 
investigated the ability of estrogen to regulate microglial phagocytic clearance of apoptotic cells in 69 
unstimulated and pro-inflammatory conditions, and the consequences of estrogen treatment upon 70 
microglial phenotype, focussing on the central pro-resolving actor annexin A1.  71 
72 
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Materials & Methods 73 
Drugs  74 
Laboratory reagents and culture media were purchased from Sigma-Aldrich (Poole, UK) unless 75 
otherwise stated. The selective estrogen receptor alpha (ERα) agonist 4,4',4''-(4-propyl-[1H]-pyrazole-76 
1,3,5--triyl)trisphenol (PPT), the selective estrogen receptor beta (ERβ) agonist diarylpropionitrile 77 
(DPN), the selective G-protein coupled estrogen receptor (GPER) agonist (±)-1-[(3aR*,4S*,9bS*)-4-78 
(6-Bromo-1,-3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclop-enta[c]quinolin-8-yl]-ethanone 79 
(G1), the selective ERβ antagonist 4-[2-phenyl-5,7-bis (trifluoromethyl-)pyrazolo[1,5-a]pyrimidin-3-80 
yl] phenol (PHTPP) and the selective GPER antagonist (3aS*,4R*,9bR*)-4-(6-Bromo-1,3-81 
benz-odioxol-5-yl)-3a,4,5,9b-3H-cyclopenta[c]quinolone (G15) were all purchased from Tocris 82 
Bioscience, UK.  83 
 84 
Cell Culture 85 
Murine microglial BV2 cells (25) were cultured in RPMI medium supplemented with 5% fetal calf 86 
serum, 100µM non-essential amino acids, 2mM l-alanyl-glutamine and 50µg/ml gentamycin (all 87 
ThermoFisher Scientific, Poole, UK) at 37°C in 5% CO2. PC12 cells (ATCC) were cultured in RPMI 88 
medium supplemented with 10% normal horse serum, 5% fetal calf serum, 100µM non-essential amino 89 
acids, 2mM l-alanyl-glutamine and 50µg/ml gentamycin (all ThermoFisher Scientific, UK) at 37°C in 90 
5% CO2. 91 
 92 
Knockdown of AnxA1 expression  93 
BV2 cells (1 × 105 cells per well) were transfected with shRNA plasmids targeting murine AnxA1 from 94 
the MISSION TRC shRNA collection (Sigma-Aldrich, St. Louis, MO, USA), or with an empty plasmid 95 
control (termed pKCON). Cells were transfected for 48h using FuGENE HD (Promega, Madison, 96 
Wisconsin, USA) according to the manufacturer's instructions, followed by selection for stable clones 97 
using puromycin (Promega, Madison, Wisconsin, USA). Transfection was confirmed by western blot 98 
analysis. 99 
 100 
Phagocytosis Assay 101 
Phagocytosis was assessed as detailed previously (21). Briefly, PC12 cells were fluorescently labelled 102 
with 5-chloromethylfluorescein diacetate (CMFDA; Thermofisher Scientific, UK) according to the 103 
manufacturer’s instructions, and were treated overnight with 80µM 6-hydroxydopamine hydrobromide 104 
or 40µM Na2S2O5 vehicle to induce apoptosis. Labelled apoptotic/non-apoptotic PC12 cells were then 105 
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5 
co-cultured with previously plated BV2 cells at a ratio of 1:3 BV2:PC12 for 2h at 37C under 5% CO2. 106 
Co-cultures were rapidly washed three times with ice-cold PBS to remove non-phagocytic cells, and 107 
cells were either detached by gentle scraping using a rubber policeman for analysis by imaging 108 
cytometer, or mounted under Mowiol mounting agent for analysis by immunofluorescence microscopy 109 
as described previously (21). Cells were examined using an ImageStreamx MKII imaging cytometer 110 
and INSPIRE software (Amnis Corporation, Seattle, WA, USA), collecting a total of 10,000 events 111 
per treatment. Typical examples of phagocytic and non-phagocytic BV2 cells are presented in 112 
Supplementary Figure 1. Imaging cytometer analysis was confirmed by parallel analysis using 113 
microscopy. All experiments were performed in triplicate. 114 
 115 
Primary microglial cultures 116 
All animal work was performed under the UK Animals (Scientific Procedures) Act, 1986. Primary 117 
murine microglial cultures were prepared from 12-week-old female AnxA1 null (26) and C57BL/6 118 
wild-type mice (n=6), according to published protocols (27). Briefly, animals were transcardially 119 
perfused with ice-cold heparinised saline under pentobarbital anaesthesia and brains were removed. 120 
Tissue was cut into ~1mm3 pieces and digested by incubation with papain for 30 minutes at 37°C 121 
(1.5U/ml, Sigma, UK). Resulting cell suspensions were purified by filtration through 0.45µm cell 122 
strainers and by density gradient separation on a 75%:25%:0% Percoll-PBS gradient (GE Johnson, 123 
UK). Following washing in PBS, cells were plated at 1.5x105 cells/well in 12-well plates and cultured 124 
in DMEM supplemented with 10% FCS, 100mM nonessential amino acids, 2mM L-alanyl-glutamine, 125 
50mg/ml gentamycin (all Life Technologies, UK) and 10ng/ml M-CSF (ThermoFisher Scientific, UK) 126 
at 37°C in 5% CO2 for 10 days prior to experimentation. Phagocytosis assays were performed by 127 
microscopy as described above, with the additional step that cultures were immunostained for Iba1 to 128 
identify microglia as described previously (21). 129 
 130 
Flow cytometry analysis 131 
BV2 cells were fixed by incubation in 2% formaldehyde for 10 minutes prior to labelling for 45 minutes 132 
at 4°C with anti-AnxA1 50ng/ml (21), mouse anti-human ERα 4µg/ml (sc-71064, Santa Cruz 133 
Biotechnology Inc., Santa Cruz,  USA); mouse anti-human ERβ 4µg/ml (sc-53494, Santa Cruz 134 
Biotechnology Inc.); goat anti-mouse GPER 5µg/ml (AF5534, R&D Systems Inc., Minneapolis, USA), 135 
APC-conjugated rat anti-mouse CD40 2.5µg/ml, PE-conjugated rat anti-mouse CD206 5µg/ml, or 136 
appropriate isotype controls (Catalogue Nos. 17-0401-82 and 12-2061-82 respectively, both 137 
ThermoFisher Scientific, UK). Cells were then washed in PBS and, where appropriate, incubated at 138 
4°C for 30 min with an AF488-conjugated secondary antibody (AnxA1, ERα, ERβ: goat anti-mouse 139 
IgG, GPER chicken anti-goat IgG, both diluted 1:300). Inclusion of 0.025% saponin at all stages of the 140 
immunostaining process was used to define total vs. surface AnxA1 expression. In all cases, 20,000 141 
events were acquired using a FACSCalibur flow cytometer (BD Biosciences, Cowley, UK) equipped 142 
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with a 488nm argon laser; data was analysed using FlowJo 8.8.2 software (Treestar Inc, Stanford, CA, 143 
USA) with positive events being compared to appropriate secondary antibody or isotype controls. 144 
 145 
Quantitative RT-PCR 146 
Total RNA was extracted using the RNeasy mini kit and genomic DNA was removed by on-column 147 
digestion using the RNase-Free DNase set, following the manufacturer's instructions (Qiagen, 148 
Crawley, UK). cDNA was synthesized using 1μg of pooled RNA from at least three replicates using 149 
SuperScript III Reverse Transcriptase (ThermoFisher Scientific, UK). Real-time PCR was performed 150 
in triplicate, with 200ng of cDNA per well, 1μl of primers, and Power SYBR Green PCR master mix 151 
(Applied Biosystems, Warrington, UK), using the ABI Prism 7900HT sequence detection system 152 
(Applied Biosystems, UK). The following QuantiTect primers (Qiagen, UK) were used: ribosomal 153 
protein L32 (Rpl32; QT00131992), AnxA1 (QT00145915). A dissociation step was always included 154 
to confirm the absence of unspecific products. Relative expression was calculated as 2-ΔΔCT using Rpl32 155 
as an endogenous control. 156 
 157 
ELISA 158 
TNF, was assayed by murine-specific sandwich ELISA using commercially available kits, according 159 
to the manufacturer’s protocols (ThermoFisher Scientific, UK). AnxA1 was assayed using an in-house 160 
ELISA. Briefly, a 96-well plate coated with 10μg/well of a murine monoclonal anti-ANXA1 Ab was 161 
blocked with 1% FCS in 50mM Na2CO3 and 50mM NaHCO3 (pH 9.6) for 1h at 37°C, washed, and 162 
samples and a standard series of hrANXA1 were then added to the plate in triplicate and incubated for 163 
1h at 37°C. Wells were washed, and incubated with a rabbit anti-ANXA1 polyclonal Ab, diluted 1:1000 164 
(Thermofisher Scientific, UK) for 1 h at 37°C. Wells were washed and incubated with HRP-conjugated 165 
sheep anti-rabbit polyclonal antiserum (1:500, Bio-Rad Antibodies, UK) for 1h at 37°C. Plates were 166 
washed and incubated with 3,3′,5,5′-tetramethylbenzidine (Sigma-Aldrich, UK) for 10 min at room 167 
temperature; reactions were stopped by addition of 0.5M H2SO4. A CLARIOstar spectrophotometer 168 
(BMG Labtech, Germany) was used to measure absorbance at 450nm; minimum sensitivity was 169 
1.4ng/ml. Nitric oxide production was assessed using the Griess reaction for its stable proxy nitrite 170 
(28). Briefly, 100μl/well culture medium was incubated with an equal volume of Griess reagent (1% 171 
sulfanilamide, 0.1% naphthylethylenediamine dihydrochloride, 5% phosphoric acid) for 15 min, prior 172 
to measurement of absorbance at 540nm using a CLARIOstar spectrophotometer (BMG Labtech, 173 
Germany). Nitrite production was determined by comparison with a NaNO2 standard curve; minimum 174 
sensitivity was 3μM. 175 
 176 
Western blot analysis 177 
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Samples boiled in 6× Laemmli buffer were subjected to standard SDS-PAGE (10%) and 178 
electrophoretically blotted onto Immobilon-P polyvinylidene difluoride membranes (Merck, UK). 179 
Total protein was quantified using Ponceau S staining (Merck, UK) and membranes were blotted for 180 
AnxA1 using an antibody raised against murine AnxA1 (1:1000; ThermoFisher Scientific, UK) in Tris-181 
buffer saline solution containing 0.1% Tween-20 and 5% (w/v) nonfat dry milk overnight at 4°C. 182 
Membranes were washed with Tris-buffer saline solution containing 0.1% Tween-20, and incubated 183 
with secondary antibody (horseradish peroxidase–conjugated goat anti-rabbit 1:5000; ThermoFisher 184 
Scientific, UK), for 2h at room temperature. Proteins were then detected using the enhanced 185 
chemiluminescence detection kit and visualized on Hyperfilm (Amersham Biosciences, Amersham, 186 
UK). Films were digitised and analysed using ImageJ 1.51w software (National Institutes of Health). 187 
 188 
Statistical Analysis 189 
All quantified data are derived from at least three independent experiments, performed in triplicate, 190 
and are expressed as the mean ± standard error of the mean. Data were analysed by one- or two-way 191 
ANOVA as appropriate, with post hoc comparison using Tukey’s HSD t-test. In all cases, p ≤ 0.05 was 192 
taken as indicating statistical significance. 193 
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Results 195 
Estradiol modulates microglial phagocytosis in a receptor-specific manner 196 
Initial analysis by flow cytometry confirmed the expression of all three principal estrogen receptors 197 
(ERα, ERβ and the G-protein coupled estrogen receptor GPER) are expressed by BV2 microglia (Fig. 198 
1A). We then investigated the ability of estrogen to modulate the phagocytosis of apoptotic PC12 cells 199 
by BV2 cells. Exposure of BV2 microglia to 17-estradiol dose- and time-dependently enhanced the 200 
phagocytic uptake of apoptotic cells, with greatest impact after 16h treatment and at 100nM (Fig. 1B-201 
C).  202 
 203 
To determine which of the three estrogen receptors were responsible for the pro-phagocytic effects of 204 
estradiol, we examined the effect of treatment with specific pharmacological agonists. Treatment of 205 
BV2 cells for 16h with the ER selective agonist PPT was without effect (Fig. 2A) but treatment with 206 
the ER agonist DPN significantly and dose-dependently enhanced phagocytosis (Fig. 2B). In contrast, 207 
16h exposure to the GPER agonist G1 dose-dependently attenuated the ability of microglia to 208 
phagocytose apoptotic cells (Fig. 2C). Furthering this analysis, we studied the effects of the ERβ 209 
antagonist PHTPP or the GPER antagonist G15 (each administered at their respective IC50 values) 210 
upon the response of BV2 cells to estradiol. Pre-treatment with either antagonist alone had no effect 211 
on phagocytosis of apoptotic cells, but administration of PHTPP almost completely inhibited the pro-212 
phagocytic effect of estradiol (Fig. 2D). In contrast, pre-treatment with G15 significantly potentiated 213 
apoptotic cell clearance by BV2 cells treated with estradiol (Fig. 2E). 214 
  215 
To validate the pro-phagocytic effects of estrogen, we examined whether primary microglia derived 216 
from adult mouse brain would respond similarly to estradiol or its receptor-specific mimetics.  Primary 217 
microglia were significantly more efficient than BV2 cells at phagocytosing apoptotic PC12 cells, but 218 
they nonetheless responded in a similar way to estrogen receptor ligand treatment, with estradiol or 219 
DPN treatment both potentiating phagocytosis and G1 treatment impairing it (Fig. 2F). Together, these 220 
data strongly indicate that estradiol exerts dual, and opposing, effects upon microglial phagocytosis 221 
acting via both ERβ and GPER. 222 
 223 
Estradiol promotes microglial phagocytosis through the mobilization of the pro-phagocytic factor, 224 
annexin A1 225 
We have previously shown the microglia-secreted protein annexin A1 (AnxA1) to serve as an 226 
important “eat me” signal for phagocytosis following its release from microglia and subsequent binding 227 
to exposed phosphatidylserine on the apoptotic cell surface (21). As we and others have shown this 228 
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protein to mediate some of the actions of estradiol in other contexts (22,29), we hypothesized that 229 
mobilization of AnxA1 may underlie the ERβ-dependent pro-phagocytic effects of estradiol. We 230 
therefore compared the effects of the hormone upon phagocytic behaviour of primary microglia derived 231 
from adult wild-type and AnxA1 null mice. Pre-treatment of primary microglia from wild-type animals 232 
with estradiol significantly increased apoptotic cell phagocytosis as expected, but this was not the case 233 
in microglia from AnxA1 null mice, where estradiol not only failed to augment microglial 234 
phagocytosis, but actually inhibited it (Fig. 3A). 235 
 236 
Given the importance of AnxA1 secretion from microglia for efficient phagocytosis, we investigated 237 
how treatment with estrogen or its receptor-specific mimetics would affect the cellular localisation of 238 
the protein. Exposure of BV2 cells to either estradiol or the ERβ agonist DPN increased AnxA1 mRNA 239 
and total protein content (Fig. 3B, C), and in the case of DPN also increased cell surface AnxA1 240 
expression (Fig. 3D). Moreover, both ligands significantly induced protein release into the culture 241 
medium (Fig. 3E). In contrast, treatment with the GPER agonist G1 had no significant effect upon 242 
AnxA1 mRNA (Fig. 3B) or secreted protein (Fig. 3E), but significantly enhanced total AnxA1 content 243 
(Fig. 3C) whilst decreasing cell surface protein (Fig. 3D), strongly suggesting increased intracellular 244 
accumulation of the protein.  245 
 246 
Estradiol regulates inflammatory microglial activation, promoting resolution 247 
Outside of development and certain defined areas of the brain, non-phlogistic neuronal apoptosis is 248 
rare, with cell death being more commonly associated with neuroinflammation and disease (30). We 249 
therefore investigated the effects of estradiol upon microglia under inflammatory conditions, modelled 250 
by exposure to bacterial endotoxin (21,31).  As previously described (21), pre-exposure of BV2 cells 251 
to 50ng/ml LPS for 18h significantly increased the inappropriate phagocytosis of non-apoptotic cells, 252 
but this was markedly attenuated by subsequent (2h after LPS stimulation) addition of estradiol or 253 
DPN, but not G1, indicative of an ER-mediated action (Fig. 4A). Similarly, LPS-induced production 254 
of intracellular reactive oxygen species was reduced by treatment with estradiol and DPN, but not G1 255 
(Fig. 4B). In contrast, estradiol, DPN and G1 were all able to attenuate LPS-induced production of the 256 
inflammatory mediators TNFα and nitric oxide (Fig. 4C, D). Characterization of BV2 cell surface 257 
markers of inflammatory phenotype revealed that treatment with estradiol, DPN or G1 could attenuate 258 
LPS-induced expression of the pro-inflammatory marker CD40 (Fig. 4E, typical profiles 259 
Supplementary Fig. 1A) and prevent LPS-induced suppression of the anti-inflammatory marker CD206 260 
(Fig. 4F, typical profiles Supplementary Fig. 1B). Together these data suggest that estrogen receptor 261 
activation could limit the pro-inflammatory stimulation of microglia, with significant roles for both 262 
ERβ and G1. 263 
 264 
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Given the major pro-resolving and anti-inflammatory functions of AnxA1 identified from studies of 265 
other immune cells (32), and our previous detection of a key mediating role for this protein in estrogen-266 
induced phagocytosis, we hypothesised that it may similarly mediate the anti-inflammatory actions of 267 
estrogen and its receptor mimetics. We therefore stably transfected BV2 cells with a lentiviral vector 268 
bearing an shRNA sequence targeting AnxA1 to reduce expression of the protein (Supplementary Fig. 269 
2) and investigated whether the anti-inflammatory effects of estrogen or its mimetics were maintained. 270 
Knock-down of AnxA1 in this way significantly impaired the ability of estradiol, DPN or G1 to reverse 271 
LPS-induced TNFα release (Fig. 5A), but did not affect the inhibitory effects of estradiol, DPN or G1 272 
on LPS-induced nitric oxide release (Fig. 5B). Suppression of AnxA1 expression did however, reverse 273 
the effects of estradiol, DPN or G1 on both CD40 (Fig. 5C) and CD206 (Fig. 5D) expression, 274 
confirming an important role for AnxA1 in mediating many, although not all, of the anti-inflammatory 275 
actions of estrogen. 276 
277 
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Discussion 278 
Estrogen is increasingly recognised as a powerful modulator of immune cell activity, able to regulate 279 
cells of both the innate (33) and adaptive (2) arms of the immune system, actions which contribute to 280 
the sex differences commonly seen in inflammatory disorders. Inflammatory diseases of the CNS, 281 
including such major conditions as Alzheimer’s disease, Parkinson’s disease and multiple sclerosis, 282 
have similarly been shown to be sexually dimorphic in incidence and/or symptom severity (34,35). 283 
Whilst multiple factors undoubtedly contribute to these sex differences, direct neuroprotective effects 284 
of estrogen are strongly supported (36,37). For many years, studies have focussed on the directly 285 
neuroprotective actions of estrogen upon neurones (38), but more recent attention has been given to 286 
the modulatory effects of the hormone upon microglial behaviour, given the importance of these cells 287 
in many neurological disorders (31,39–41). In this study, we have identified the ability of estrogen to 288 
modulate a key aspect of microglial function in disease, the removal of apoptotic cells. We describe a 289 
clear, receptor-specific, modulatory action of the principal estrogen 17β-estradiol upon microglial 290 
clearance of apoptotic cells, and highlight the ability of the steroid to suppress inflammatory microglial 291 
activation. Moreover, we reveal a central role for the powerful pro-resolving protein AnxA1 in 292 
mediating both the pro-efferocytosis and anti-inflammatory effects of estrogen upon microglia.  293 
 294 
Clearance of apoptotic cells by phagocytosis is critical for the maintenance of healthy tissue, as 295 
apoptotic cells that are not removed will progress to secondary necrosis and become significant 296 
inflammatory foci themselves (42). Microglia are the principal phagocytes of the CNS and play a 297 
central role in this process, a particularly important action given the susceptibility of neurones to 298 
inflammatory damage (43). Our data reveal estrogen to strongly potentiate microglial phagocytosis of 299 
apoptotic cells, acting through induction of AnxA1 expression and secretion. We have previously 300 
shown AnxA1 to induce a non-phlogistic phenotype in microglia post-phagocytosis (21), strongly 301 
suggesting that its modulation by estrogen is a significant component of the hormone’s neuroprotective 302 
effects. Previous work has suggested that estrogen can promote phagocytosis by peripheral 303 
macrophages (44,45), acting primarily through ERα. In contrast, whilst we identified ERα expression 304 
in microglia, activation of this receptor with the specific ERα agonist PPT had little impact on 305 
phagocytosis, with much clearer roles for the alternative estrogen receptors ERβ and GPER.  306 
 307 
Whilst the overall effect of 17β-estradiol was to stimulate microglial phagocytosis, pharmacological 308 
analysis of the specific receptors involved in this process revealed an intriguing distinction between 309 
ERβ and GPER, with ERβ acting to promote phagocytosis and GPER inhibiting it. The mechanism 310 
underlying this effect appears to revolve around differential effects upon AnxA1 localisation; ERβ 311 
activation increased AnxA1 synthesis and release, whilst GPER stimulation led to intracellular AnxA1 312 
accumulation and a reduction in secreted protein. The pro-phagocytic actions of AnxA1 are dependent 313 
upon its secretion from microglia and consequent binding to phosphatidylserine on apoptotic target 314 
cells (21), hence the negative effects of GPER stimulation upon AnxA1 release presumably underlies 315 
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the effects of this receptor upon phagocytosis. Interestingly, this dichotomy of effect was not replicated 316 
in the effects of estrogen receptor activation upon microglial phenotype, with both ERβ and GPER 317 
selective ligands being equipotent in ameliorating LPS-induced pro-inflammatory signs. This finding 318 
accords well with published studies that show exogenous administration of the GPER agonist G1 to 319 
prevent inflammatory microglial activation in vivo (46–48), and that identify a mediatory role for 320 
GPER in the anti-inflammatory effects of estrogen in cerebral ischaemia (49). These anti-inflammatory 321 
effects of estrogen or its receptor-specific mimetics again appeared to be mediated in large part through 322 
AnxA1, with microglia stably bearing AnxA1-targeting shRNA sequences showing a clear impairment 323 
in many of the anti-inflammatory actions of estrogen and its mimetics. 324 
 325 
Our findings reinforce the importance of AnxA1 in the nervous system response to injury (50), with 326 
microglia lacking AnxA1 being severely impaired in their phagocytic ability. Moreover, such 327 
microglia show a markedly altered response to estradiol with exposure to the hormone actually 328 
inhibiting phagocytosis, and inducing only limited anti-inflammatory actions. These data thus reinforce 329 
the complexity of the systems that have evolved to regulate microglial function. Moreover, this work 330 
highlights the potent regulatory action of estrogen upon AnxA1 expression and activity (22,23), and 331 
extends this role to the cells of the CNS. Thus, complementing its long-studied role as a mediator of 332 
glucocorticoid immunomodulatory action (32), our results further emphasise the importance of AnxA1 333 
in the anti-inflammatory effects of female sex hormones. 334 
 335 
Local up-regulation of aromatase expression and consequent estrogen production is a key part of the 336 
response to CNS injury (4,5,51), acting to limit damage and preserve tissue integrity. Where and how 337 
estrogen exerts its protective effects is less clear however, but blockade of estrogen production by 338 
genetic deletion of aromatase leads to significantly enhanced post-injury gliosis (52). The role of 339 
microglia in such injury-induced gliosis is complex, as these cells show dramatic and dynamic changes 340 
in phenotype (53), and have the potential to be both harmful and protective to surrounding neurones 341 
(54). Our findings suggest that a major action of estrogen upon microglia is to promote their more 342 
protective functions, enhancing the efferocytosis of damaged/dying cells and limiting expression of 343 
pro-inflammatory features. These actions are supported by numerous studies showing exogenous 344 
estrogen to be protective in models of neuroinflammatory/neurotoxic damage (37,55), and particularly 345 
by previous work identifying estrogen as an anti-inflammatory modifier of microglial phenotype (56–346 
62). Together with these reports, our study places estrogen as a significant pro-resolving mediator 347 
within the brain, acting to stimulate the removal of cellular debris post-injury and to promote an anti-348 
inflammatory environment, highlighting its role as a major part of the brain’s endogenous defence 349 
mechanisms.  350 
 351 
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Figure Legends 555 
 556 
Figure 1: Estrogen promotes microglial phagocytosis of apoptotic cells. A) BV2 cells express all 557 
three principal estrogen receptors ER, ER and GPR30, as determined by flow cytometry. Data are 558 
representative histograms of n=3 independent experiments. Exposure of BV2 cells to 17-estradiol 559 
enhances their ability to phagocytose apoptotic (grey) but not non-apoptotic (white) PC12 cells in a B) 560 
dose and C) time-dependent manner; data are mean  sem, n=3, *p<0.05 vs. untreated controls. 561 
 562 
Figure 2: Estrogen has receptor specific effects upon microglial phagocytosis. A-C) Treatment of 563 
BV2 cells for 16h with estradiol (E2) or selective agonists for A) ER (PPT), B) ER (DPN) or C) 564 
GPER (G1) revealed receptor dependent effects upon microglial phagocytosis, with activation of ER 565 
promoting and GPER inhibiting phagocytic activity; ER activation had no effect on phagocytosis; 566 
data are means  sem, n=3, *p<0.05 vs. untreated controls. D) Pre-treatment of microglia with the 567 
selective ER antagonist PHTPP (200nM, 15 minute pre-treatment) prevented the stimulatory effect 568 
of estradiol (100nM, 16h) upon microglial phagocytosis of apoptotic cells; data are means  sem, n=3, 569 
*p<0.05 vs. untreated controls, +p<0.05 vs. 17-estradiol treatment. E) Pre-treatment of microglia with 570 
the selective GPER antagonist G1 (200nM, 15 minute pre-treatment) enhanced the stimulatory effect 571 
of estradiol (100nM, 16h) upon microglial phagocytosis of apoptotic cells; data are means  sem, n=3, 572 
*p<0.05 vs. untreated controls, +p<0.05 vs. 17-estradiol treatment. F) Treatment of primary murine 573 
microglia for 16h with 17β-estradiol or DPN enhanced phagocytosis of apoptotic cells, whilst treatment 574 
with G1 inhibited phagocytosis; data are means ± sem, n=3, *p<0.05 vs. untreated controls, +p<0.05 575 
vs. 17-estradiol treatment.  576 
 577 
Figure 3: The pro-phagocytic effects of estrogen via ER require mobilization of annexin A1. A) 578 
Treatment of primary microglia from wild-type mice with 17-estradiol (100nM, 16h) promotes 579 
phagocytosis of apoptotic PC12 cells, whereas similar treatment of AnxA1-/- primary microglia causes 580 
a significant further inhibition in their phagocytic ability; data are means  sem, n=3, *p<0.05 vs. 581 
untreated controls, +p<0.05 vs. similarly treated wild-type group. B) Treatment of BV2 cells for 16h 582 
with 17-estradiol or the ER agonist DPN, but not the GPER agonist G1, enhances production of 583 
AnxA1 mRNA; data are means  sem, n=3, *p<0.05 vs. untreated controls. C) Treatment of BV2 cells 584 
for 16h with 17-estradiol, DPN or G1 enhances total cellular AnxA1 content; data are means  sem, 585 
n=3, *p<0.05 vs. untreated controls. D) Treatment of BV2 cells for 16h with DPN enhances, whilst 586 
similar treatment with G1 reduces, surface expression of AnxA1; data are means  sem, n=3, *p<0.05 587 
vs. untreated controls. E) Treatment of BV2 cells for 16h with 17-estradiol or DPN but not G1 588 
enhances release of AnxA1 into the culture medium; data are means  sem, n=3, *p<0.05 vs. untreated 589 
controls.  590 
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 591 
Figure 4: Estrogen promotes an anti-inflammatory microglial phenotype. A) Pre-treatment of 592 
BV2 cells for 2h with 50ng/ml bacterial lipopolysaccharide (LPS) induces the phagocytosis of non-593 
apoptotic PC12 cells, an effect reversed by subsequent treatment (16h) with either 17-estradiol or 594 
DPN, but not G1; data are means  sem, n=3, *p<0.05 vs. respective control cells, +p<0.05 vs. LPS 595 
treatment alone. B) Treatment of BV2 cells with 17-estradiol or DPN but not G1 (16h) suppresses 596 
LPS-induced reactive oxygen species production (2h pre-treatment); data are means  sem, n=3, 597 
*p<0.05 vs. LPS-treated controls. C) Treatment of BV2 cells (16h) with 17-estradiol or DPN but not 598 
G1 (16h) limits LPS-induced production of the pro-inflammatory cytokine TNF (2h pre-treatment); 599 
data are means  sem, n=3, *p<0.05 vs. respective control cells, +p<0.05 vs. LPS treatment alone. D) 600 
Treatment of BV2 cells with 17-estradiol, DPN or G1 (16h) suppresses LPS-induced production of 601 
nitrite (2h pre-treatment; baseline nitrite production was below detection limits); data are means  sem, 602 
n=3, *p<0.05 vs. LPS-treated control cells. E) Treatment of BV2 cells with 17-estradiol, DPN or G1 603 
(16h) suppresses LPS-induced surface expression of the pro-inflammatory marker CD40 (2h pre-604 
treatment); data are means  sem, n=3, *p<0.05 vs. untreated control cells, +p<0.05 vs. LPS-treated 605 
control cells. F) Treatment of BV2 cells with 17-estradiol, DPN or G1 (16h) reverses the LPS-induced 606 
loss of surface expression of the anti-inflammatory marker CD206 (2h pre-treatment); data are means 607 
 sem, n=3, *p<0.05 vs. respective control cells, +p<0.05 vs. LPS treatment alone.  608 
 609 
Figure 5: The anti-inflammatory effects of estrogen are largely dependent upon AnxA1 610 
expression. A) Stable transfection of BV2 cells with an shRNA sequence targeting AnxA1, but not 611 
with an empty plasmid control (pKCON), inhibits the ability of estradiol, DPN or G1 (16h) to suppress 612 
LPS-induced TNFα production (2h pre-treatment); data are means ± sem, n=3, *p<0.05 vs. LPS-treated 613 
control cells. B) Neither stable transfection of BV2 cells with an empty plasmid control (pKCON) nor 614 
with an shRNA sequence targeting AnxA1 affects the ability of estradiol, DPN or G1 (16h) to suppress 615 
LPS-induced nitrite production (2h pre-treatment); data are means ± sem, n=3, *p<0.05 vs. LPS-treated 616 
control cells. C) Stable transfection of BV2 cells with an shRNA sequence targeting AnxA1, but not 617 
with an empty plasmid control (pKCON), inhibits the ability of estradiol, DPN or G1 (16h) to suppress 618 
LPS-induced surface expression of the pro-inflammatory marker CD40 (2h pre-treatment); data are 619 
means ± sem, n=3, *p<0.05 vs. LPS-treated control cells. D) Stable transfection of BV2 cells with an 620 
shRNA sequence targeting AnxA1, but not with an empty plasmid control (pKCON), inhibits the 621 
ability of estradiol, DPN or G1 (16h) to reverse LPS-suppressed expression of the anti-inflammatory 622 
marker CD206 (2h pre-treatment); data are means ± sem, n=3, *p<0.05 vs. LPS-treated control cells. 623 
 624 
Supplemental Figure 1: Typical flow cytometry profiles for phagocytosing BV2 cells, shown as A) 625 
histograms indicating BV2 cell phagocytosis in control conditions and following treatment with 626 
estradiol (100nM, 16h), and B) ImageStreamx MKII imaging cytometer images of BV2 cells exposed 627 
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to CMFDA-labelled apoptotic PC12 cells, identifying typical cells that were positive and negative for 628 
phagocytosis. 629 
 630 
Supplementary Figure 2: Typical surface expression profiles for A) CD40 and B) CD206 on BV2 631 
cells treated for 16h with estradiol (100nM), DPN (850pM) or G1 (20nM) ± 2h prior treatment with 632 
LPS (50ng/ml). 633 
 634 
Supplementary Figure 3: Western blot analysis of AnxA1 expression in three independent samples 635 
of wild-type BV2 cells or BV2 cells stably transfected with an empty control plasmid (pKCON) or the 636 
same plasmid bearing an shRNA sequence for AnxA1. Comparison is made with total loaded protein, 637 
as visualised by Ponceau S staining. 638 
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